Try our Advanced Search for more refined results

Purdue Pharma L.P.

Track this case

Case overview

Case Number:

7:19-bk-23649

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 17, 2020

    Purdue Pharma Gets Court Approval For $8B Deal With Feds

    A New York bankruptcy Judge on Tuesday approved Purdue Pharma's $8 billion settlement of federal felony charges stemming from its OxyContin sales and said Purdue's former owning family can pay $225 million in fines without violating court orders.

  2. November 16, 2020

    Feds Say $225M Sackler Fine To Go To Medicare, Medicaid

    The U.S. attorney's office has told a New York bankruptcy judge that nearly all of the $225 million settlement of federal opioid litigation against the former owning family of Purdue Pharma will go into the general Medicare and Medicaid budget.

  3. November 12, 2020

    States Say $8.3B Purdue Opioid Deal Flouts Bankruptcy Rules

    A group of states on Tuesday voiced opposition to Purdue Pharma LP's $8 billion OxyContin settlement with the federal government, saying that the plan puts the bankruptcy case parties in a "straitjacket."

  4. October 28, 2020

    Fight Over Sackler Deal On Hold For Purdue Ch. 11 Plan Talks

    Whether Purdue Pharma's unsecured creditors can stop the Sackler family from using corporate funds to pay a $225 million fine that's part of the $8 billion OxyContin settlement with the federal government will wait for parties to negotiate over the company's Ch. 11 plan, a New York bankruptcy judge said Wednesday.

  5. October 27, 2020

    Purdue Creditors Object To Sackler Part Of $8B DOJ Deal

    Creditors of drugmaker Purdue Pharma on Tuesday asked a New York bankruptcy judge to bar the use of corporate funds to pay the $225 million that members of its former owning family owe the government under the $8 billion OxyContin sale settlement announced last week.

  6. October 21, 2020

    Sackler Factor Could Sink Purdue's $8B Opioid Deal With DOJ

    While the $8 billion criminal and civil settlement OxyContin maker Purdue Pharma made with the federal government resolves the Chapter 11 claim from its single largest creditor, it could draw fatal opposition in bankruptcy court for failing to address the potential liability related to the Sackler family's ownership of the company.

  7. October 16, 2020

    Purdue, Sacklers Say Atty-Client Privilege Shields Documents

    Purdue Pharma and members of its former owning family are asking a New York bankruptcy judge to reject new document requests by the unsecured creditors committee in its Chapter 11 case, saying the committee is seeking privileged communications without justification.

  8. October 14, 2020

    State AGs Bash DOJ's Proposed Opioid Deal With Purdue

    Dozens of state attorneys general on Wednesday slammed the U.S. Department of Justice's plan to preserve Purdue Pharma as a public beneficiary trust through a proposed settlement that could end federal liability the company faces for its alleged role in the opioid epidemic.

  9. September 30, 2020

    Purdue Pharma Gets OK For Payments, Opioid Suit Shield

    A New York bankruptcy judge on Wednesday gave Purdue Pharma another five months free from opioid suits and permission to make $26 million in employee retention payments after being told claim distribution mediation between the drugmaker and its creditors is bearing fruit.

  10. September 22, 2020

    Trustee Bristles At New $45M Purdue Bid For Ch. 11 Bonuses

    The Office of the United States Trustee objected Tuesday to a proposed $45 million Chapter 11 bonus plan from bankrupt painkiller maker Purdue Pharma, saying the company has already been approved to pay $38 million in retention and incentive bonuses to employees and the new plan doesn't contain meaningful benchmarks.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!